Myths St. Louis parents hold about helping an adult child

Parents in St. Louis who are watching an adult son or daughter struggle with depression tend to run on a mix of love, fear, and folk wisdom. Some of that wisdom helps. Some of it quietly makes the conversation about new treatments harder than it needs to be.

Here are six beliefs parents commonly hold about helping an adult child consider ketamine-based depression care. Each is weighed against the medical facts and against the June 2026 survey of 443 Midwest adults our publisher paid to run. The survey numbers are final and validated, and most describe the whole sample.

"If my kid is skeptical, the answer is already no."

Reality: Skepticism and refusal are different things. Our survey tested gut reactions to ketamine-based depression and PTSD care; roughly one in five, 21 percent, called themselves skeptical. But flat-out negative reactions were much rarer, at 9 percent. And the most common reaction of all was "cautious but open," at 34 percent. In the St. Louis TV market, a small group of 31 respondents, 58 percent were open to it.

A skeptical adult is often asking good questions: Is this safe? Is it legitimate? What happens in the room? Answering those questions honestly, or helping them get answers from a doctor, is a very different project from overcoming a no.

"A good parent pushes hard when it matters."

Reality: With adults, pushing tends to backfire. Caution hardens when someone feels cornered. Your son or daughter is an adult with the legal right to make their own medical decisions, and the decision to try a treatment like esketamine belongs to them and their clinician.

What works better is an open door. Share information once, with permission. Offer practical help. Then let them come back to it. A parent who is calm and available is often more persuasive over months than one who argues for an afternoon.

"Since they're an adult, I have no role at all."

Reality: Your role changes, but it does not vanish. In our survey, 18 percent said a nudge from a close friend or relative would be enough to get them to try this kind of care. That is far behind a doctor's recommendation, which was the answer for 74 percent, but it is well ahead of ads, at 2 percent.

Parents often matter most at the edges: noticing that things are not getting better, suggesting a doctor visit, driving to appointments, checking insurance if your child is under 26 and still on your plan, and being a calm presence afterward. If your child wants you to know details from their clinician, they can sign a release. If they do not, respect that.

"Ketamine is ketamine."

Reality: Not in the way that matters for your child's safety. St. Louis families will see ads for several different things that share the name:

• Esketamine (Spravato) is a spray taken through the nose that holds FDA approval for two adult uses: depression that earlier treatment did not lift, and major depression marked by acute suicidal ideation or behavior. Patients use it only inside certified centers and are observed for two hours or longer after each dose.
• IV ketamine infusions put an approved anesthetic to off-label use and are offered by specialty clinics in the St. Louis area and elsewhere, typically for cash.
• At-home ketamine prescribed over telehealth is off-label as well, and nobody watches the patient take it. Federal regulators have flagged that risk.

Knowing these distinctions lets you ask any clinic a sharp first question: which one do you offer? For the approved option, Brain Recovery Centers lays out how Spravato sessions are run.

"If it were a real option, my kid would have heard of it."

Reality: Hardly anyone knows the name. We asked about Spravato by name. Seventy-three percent of respondents did not know it at all, a fifth knew only the name, and just 6 percent could explain it. Awareness of the approved treatment is remarkably low across the region.

That is why a gentle introduction often beats persuasion. "Did you know the FDA approved something for depression that regular medication hasn't touched?" invites curiosity. It does not demand agreement.

"The right article or video will convince them."

Reality: Information helps, but it rarely closes the decision. The persuasive voice in our survey was overwhelmingly a person's own doctor. Ads were picked by 2 percent, and a trusted podcast host by only 1 percent. As a first stop, 56 percent picked a primary care doctor; just 12 percent would begin by typing into a search engine.

So if you share an article, pair it with a practical next step: "Want to raise this with your doctor? I can help you get an appointment."

What does help, in St. Louis terms

• Know where care is. Your insurer, or the locator the drugmaker runs, can list certified esketamine centers. Between St. Charles County on one edge and the Metro East on the other, distance and traffic matter for a schedule that often starts at two visits a week.
• Know that driving is off the table afterward. Nobody gets behind the wheel after a session until they have slept and it is the next day. Offering to be the driver is one of the most concrete things a parent can do.
• Check coverage quietly. If your child is on your plan, one phone call to the insurer will tell you if esketamine is on the plan and if it needs prior authorization first. Coverage topped our survey's list: 85 percent put it in their top two.
• Take care of yourself. Supporting an adult child through depression is heavy. Support groups for families of people with mental illness meet across the St. Louis area, and talking to your own doctor or a counselor is legitimate, not selfish.

Whether any treatment is right for your child is a question for their clinician. Nothing here is medical advice.

Should your child ever seem in immediate danger, or tell you suicide is on their mind, do not wait on any plan. Get 988 on the line, calling or texting; its Suicide and Crisis Lifeline counselors take parents' calls about a grown son or daughter, whatever the hour.

Methodology

Who ran it: Pollfish, on its consumer panel, with fieldwork ending June 23, 2026. Who answered: 443 people aged 18 to 64 from Ohio, Kansas, Illinois, Minnesota, Missouri, Oklahoma, Wisconsin, Nebraska, Indiana, and Iowa. Who paid: our publisher, which commissioned the survey. What we used: the final validated data, whole sample unless a named group is noted.